Literature DB >> 14569432

The effects of intraoperative fenoldopam on renal blood flow and tubular function following suprarenal aortic cross-clamping.

Quintessa Miller1, Brian D Peyton, E Jerry Cohn, G Frank Holmes, Stuart A Harlin, Erin T Bird, Joseph G Harre, Michael L Miller, Keyan D Riley, Michael B Hogan, Addison Taylor.   

Abstract

This study evaluated the effect of fenoldopam, a selective dopamine (DA1) agonist, on renal blood flow and renal tubular function following renal ischemia induced by suprarenal aortic cross-clamping. Twenty anesthetized research pigs received either fenoldopam (10 micro g/kg/min; n = 10) or saline ( n = 10) beginning 20 min before suprarenal aortic cross-clamping and continuing for 20 min after clamp release, for a total infusion time of 160 min (120-min cross-clamp). Recordings of renal blood flow, mean arterial pressure, and heart rate were taken at baseline, during cross-clamping, and immediately postclamp. Ischemic renal injury was evaluated by serum creatinine and by histologic grading of acute tubular necrosis. Treatment with fenoldopam increased renal blood flow in comparison to that in the control group ( p = 0.03). The mean creatinine increase from baseline at 6 hr and 18 hr after cross-clamp removal for the fenoldopam-treated group was significantly less than that in the control group ( p < 0.001). On histologic evaluation, the mean score for the degree of tubular necrosis was significantly higher in the control group ( p = 0.02), indicating less derangement of tubular morphology in the fenoldopam group. This study demonstrated that the intraoperative use of a continuous infusion of fenoldopam during suprarenal aortic cross-clamping results in increased renal blood flow, less postoperative rise in creatinine, and better preservation of tubular histology in the pig model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569432     DOI: 10.1007/s10016-003-0067-1

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  5 in total

1.  Carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine kidney ischemia/reperfusion injury.

Authors:  Šárka Matějková; Angelika Scheuerle; Florian Wagner; Oscar McCook; José Matallo; Michael Gröger; Andrea Seifritz; Bettina Stahl; Brigitta Vcelar; Enrico Calzia; Michael Georgieff; Peter Möller; Hubert Schelzig; Peter Radermacher; Florian Simon
Journal:  Intensive Care Med       Date:  2013-01-05       Impact factor: 17.440

2.  Intravenous fenoldopam for early acute kidney injury after liver transplantation.

Authors:  Gianni Biancofiore; Maria L Bindi; Mario Miccoli; Elisabetta Cerutti; Bruna Lavezzo; Laura Pucci; Massimo Bisà; Massimo Esposito; Luca Meacci; Roberto Mozzo; Chiara Stratta; Giuseppe Penno; Angelo Baggiani; Franco Filipponi
Journal:  J Anesth       Date:  2014-11-30       Impact factor: 2.078

3.  Effects of a cantaloupe melon extract/wheat gliadin biopolymer during aortic cross-clamping.

Authors:  Jochen Kick; Balázs Hauser; Hendrik Bracht; Maura Albicini; Sükrü Oter; Florian Simon; Ulrich Ehrmann; Catherine Garrel; Jörn Sträter; Uwe B Brückner; Xavier M Leverve; Hubert Schelzig; Günter Speit; Peter Radermacher; Claus-Martin Muth
Journal:  Intensive Care Med       Date:  2007-01-20       Impact factor: 17.440

4.  Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure.

Authors:  Martin Leduc; Xin Hou; David Hamel; Melanie Sanchez; Christiane Quiniou; Jean-Claude Honoré; Olivier Roy; Ankush Madaan; William Lubell; Daya R Varma; Joseph Mancini; François Duhamel; Krishna G Peri; Vincent Pichette; Nikolaus Heveker; Sylvain Chemtob
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

Review 5.  Large animal models for translational research in acute kidney injury.

Authors:  Balamurugan Packialakshmi; Ian J Stewart; David M Burmeister; Kevin K Chung; Xiaoming Zhou
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.